Raine Tina R, Harper Cynthia C, Rocca Corinne H, Fischer Richard, Padian Nancy, Klausner Jeffrey D, Darney Philip D
Center for Reproductive Health Research and Policy, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA 94110, USA.
JAMA. 2005 Jan 5;293(1):54-62. doi: 10.1001/jama.293.1.54.
It is estimated that half of unintended pregnancies could be averted if emergency contraception (EC) were easily accessible and used.
To evaluate the effect of direct access to EC through pharmacies and advance provision on reproductive health outcomes.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, single-blind, controlled trial (July 2001-June 2003) of 2117 women, ages 15 to 24 years, attending 4 California clinics providing family planning services, who were not desiring pregnancy, using long-term hormonal contraception or requesting EC.
Participants were assigned to 1 of the following groups: (1) pharmacy access to EC; (2) advance provision of 3 packs of levonorgestrel EC; or (3) clinic access (control).
Primary outcomes were use of EC, pregnancies, and sexually transmitted infections (STIs) assessed at 6 months; secondary outcomes were changes in contraceptive and condom use and sexual behavior.
Women in the pharmacy access group were no more likely to use EC (24.2%) than controls (21.0%) (P = .25). Women in the advance provision group (37.4%) were almost twice as likely to use EC than controls (21.0%) (P<.001) even though the frequency of unprotected intercourse was similar (39.8% vs 41.0%, respectively, P = .46). Only half (46.7%) of study participants who had unprotected intercourse used EC over the study period. Eight percent of participants became pregnant and 12% acquired an STI; compared with controls, women in the pharmacy access and advance provision groups did not experience a significant reduction in pregnancy rate (pharmacy access group: adjusted odds ratio [OR], 0.98; 95% confidence interval [CI], 0.58-1.64; P = .93; advance provision group: OR, 1.10; 95% CI, 0.66-1.84, P = .71) or increase in STIs (pharmacy access group: adjusted OR, 1.08, 95% CI, 0.71-1.63, P = .73; advance provision group: OR, 0.94, 95% CI, 0.62-1.44, P = .79). There were no differences in patterns of contraceptive or condom use or sexual behaviors by study group.
While removing the requirement to go through pharmacists or clinics to obtain EC increases use, the public health impact may be negligible because of high rates of unprotected intercourse and relative underutilization of the method. Given that there is clear evidence that neither pharmacy access nor advance provision compromises contraceptive or sexual behavior, it seems unreasonable to restrict access to EC to clinics.
据估计,如果紧急避孕(EC)易于获取并得到使用,那么一半的意外怀孕是可以避免的。
评估通过药店直接获取紧急避孕药物以及提前提供药物对生殖健康结果的影响。
设计、地点和参与者:一项随机、单盲、对照试验(2001年7月至2003年6月),研究对象为2117名年龄在15至24岁之间、前往加利福尼亚州4家提供计划生育服务的诊所就诊、不希望怀孕、未使用长效激素避孕方法或未要求紧急避孕的女性。
参与者被分配到以下几组之一:(1)可通过药店获取紧急避孕药物;(2)提前提供3包左炔诺孕酮紧急避孕药物;或(3)通过诊所获取(对照组)。
主要结局指标为在6个月时评估的紧急避孕药物使用情况、怀孕情况和性传播感染(STIs);次要结局指标为避孕方法和避孕套使用情况以及性行为的变化。
可通过药店获取紧急避孕药物组的女性使用紧急避孕药物的可能性(24.2%)并不比对照组(21.0%)更高(P = 0.25)。提前提供药物组的女性使用紧急避孕药物的可能性(37.4%)几乎是对照组(21.0%)的两倍(P<0.001),尽管未采取保护措施的性行为频率相似(分别为39.8%和41.0%,P = 0.46)。在研究期间,只有一半(46.7%)有未采取保护措施性行为的研究参与者使用了紧急避孕药物。8%的参与者怀孕,12%感染了性传播感染;与对照组相比,可通过药店获取紧急避孕药物组和提前提供药物组的女性怀孕率没有显著降低(可通过药店获取紧急避孕药物组:调整后的优势比[OR],0.98;95%置信区间[CI],0.58 - 1.64;P = 0.93;提前提供药物组:OR,1.10;95% CI,0.66 - 1.84,P = 0.71),性传播感染率也没有增加(可通过药店获取紧急避孕药物组:调整后的OR,1.08,95% CI,0.71 - 1.63,P = 0.73;提前提供药物组:OR,0.94,95% CI,0.62 - 1.44,P = 0.79)。各研究组在避孕方法或避孕套使用模式以及性行为方面没有差异。
虽然取消通过药剂师或诊所获取紧急避孕药物的要求会增加其使用,但由于未采取保护措施的性行为发生率较高且该方法的利用率相对较低,其对公共卫生的影响可能微不足道。鉴于有明确证据表明通过药店获取紧急避孕药物和提前提供药物均不会影响避孕措施或性行为,将紧急避孕药物的获取限制在诊所似乎不合理。